Recent studies, demonstrating the presence of inflammatory cells and their products in CNS lesions, led to the generally accepted hypothesis that at least relapsing-remitting MS is triggered by pathogenic CD4+ T cells reactive against myelin constituents [5, 19, 20]. Here, CD4 is linked to myeloid sarcoma.